Back HIV/AIDS

HIV / AIDS

Very Early Antiretroviral Therapy Does Not Prevent Immune Activation

People who started antiretroviral therapy (ART) during acute HIV infection and experienced sustained viral suppression saw a substantial decrease in immune activation markers on their CD8 T-cells after 2 years of treatment, but often not to the level seen in HIV negative individuals, according to a report in the April 15, 2013, Journal of Acquired Immune Deficiency Syndromes.

alt

Updated Opportunistic Infection Guidelines Add Info on IRIS, Hepatitis, Drug Interactions

On May 7 the National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Diseases Society of Americaannounced the release of revised Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, updating the previous version from 2009.

alt

U.S. Preventive Services Task Force Recommends Routine HIV Screening for Adolescents and Adults

On April 30 the U.S. Preventive Services Task Force (USPSTF) issued a "Grade A," or highest-level, recommendation that all adolescents and adults ages 15 through 65 years should receive routine HIV screening. "These recommendations...reinforce the importance of people everywhere knowing their HIV status and, if positive, accessing care, receiving treatment and other prevention services," said CDC's Jonathan Mermin.

alt

Efavirenz More Effective than Nevirapine for Children with HIV

HIV positive African children and adolescents treated with efavirenz (Sustiva) were less likely to experience virological failure than those using nevirapine (Viramune), according to a large comparative study published in the May 1, 2013, Journal of the American Medical Association. Nevirapine, however, is less expensive and more widely available for children in low-income countries.

alt

FDA Approves Efavirenz (Sustiva) for HIV+ Children Ages 3 Months to 3 Years

The U.S. Food and Drug Administration (FDA) announced on May 3 that it has approved a supplemental new drug application for use of efavirenz (Sustiva) by infants and young children with HIV. The new dosing recommendation includes the option to sprinkling capsule contents on food for children who are unable to swallow pills.

alt

FDA Declines Approval of Elvitegravir and Cobicistat as Stand-alone HIV Meds

The U.S. Food and Drug Administration (FDA) has rejected approval of Gilead Sciences' integrase inhibitor elvitegravir and pharmacoenhancer cobicistat -- components of the 4-in-1 Stribild quad pill -- as single agents for treatment of HIV, the company announced last week.

alt

Atripla Label Adds Drug Interactions with Hepatitis C Protease Inhibitors Boceprevir and Telaprevir

The U.S. Food and Drug Administration (FDA) announced this week that the product label information for Atripla -- the HIV single-tablet regimen containing efavirenz/tenofovir/emtricitabine -- has been updated to include information about drug-drug interactions with the hepatitis C virus protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek or Incivo).

alt